Quarterly Consolidated Statement Of Cash Flows

Immuno-Biological Laboratories Co., Ltd. - Filing #7295281

Concept As at
2024-09-30
2024-04-01 to
2024-09-30
As at
2024-03-31
As at
2023-09-30
2023-04-01 to
2023-09-30
As at
2023-03-31
Quarterly consolidated statement of cash flows
Statement of cash flows
Cash flows from operating activities
Profit (loss) before income taxes
64,211,000 JPY
29,869,000 JPY
Depreciation
6,059,000 JPY
JPY
Impairment losses
JPY
602,000 JPY
Increase (decrease) in allowance for doubtful accounts
JPY
-6,697,000 JPY
Interest and dividend income
-91,000 JPY
-47,000 JPY
Interest expenses
619,000 JPY
533,000 JPY
Foreign exchange losses (gains)
3,067,000 JPY
-2,820,000 JPY
Decrease (increase) in trade receivables
12,189,000 JPY
24,935,000 JPY
Decrease (increase) in inventories
422,000 JPY
-6,904,000 JPY
Increase (decrease) in trade payables
7,064,000 JPY
-2,298,000 JPY
Other, net
-3,367,000 JPY
-13,617,000 JPY
Subtotal
83,817,000 JPY
16,920,000 JPY
Interest and dividends received
577,000 JPY
12,000 JPY
Interest paid
-1,756,000 JPY
-550,000 JPY
Income taxes paid
-5,859,000 JPY
-9,300,000 JPY
Net cash provided by (used in) operating activities
76,778,000 JPY
7,081,000 JPY
Cash flows from investing activities
Purchase of property, plant and equipment
-35,161,000 JPY
JPY
Other, net
0 JPY
178,000 JPY
Net cash provided by (used in) investing activities
-44,161,000 JPY
-8,821,000 JPY
Cash flows from financing activities
Proceeds from long-term borrowings
JPY
10,000,000 JPY
Repayments of long-term borrowings
-41,667,000 JPY
-12,004,000 JPY
Net cash provided by (used in) financing activities
-38,857,000 JPY
2,996,000 JPY
Effect of exchange rate change on cash and cash equivalents
-3,067,000 JPY
2,820,000 JPY
Net increase (decrease) in cash and cash equivalents
-9,307,000 JPY
4,076,000 JPY
Cash and cash equivalents
665,662,000 JPY
674,969,000 JPY
566,074,000 JPY
561,997,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.